Page 165 - Read Online
P. 165
Page 12 of 29 Dastidar et al. Vessel Plus 2020;4:14 I http://dx.doi.org/10.20517/2574-1209.2019.36
Ref. [111] [112] [113] [114] [115] [116] [117] [105] [118] [103] [104] [119] [120]
Year of study 2014 2016 2019 2018 2017 2016 2014 2019 2010 2018 2014 2014 2019
In vivo/ex vivo/clinical study In vivo: nude mice bearing U87 MG glioblastoma Ex vivo: glioma C6 and U-87 MG cells using female Wister rat Ex vivo: HepG2 cell In vivo: H22 tumour-bearing mice line Ex vivo: MCG-7 cell line In vivo: MCF-7 xenograft tumour model in nude mice Ex-vivo: MDA-MB-231 cells In vivo: MDA-MB-231 orthotopic xenograft model Ex vivo: human glioblastoma cells (U87 MG) and murine BMVEC In vivo: male BALB/c nude mice wit
Mechanism of action Angiopep ligand helps in brain tumour targeting, tLyP-1 ensures tumour penetration. siRNAs inhibit VEGF production The mAb targets the liposome to tumour cells. Cis-di-ammine-di-nitro-platinum (II) In vivo: intracranial C6 glioma rat model kills cancer cells Inhibition of angiogenesis due to downregulation of VEGF VEGF overexpressed by cancer cells provides Ex vivo: MDA-MB-231 breast cancer cell the mechanism to unlock the
Table 2. Strategies of tumour-targeted drug delivery exploiting tumour vasculature
Formulation/delivery system Liposome with two peptides (Angiopep and tLyP-1) attached on the surface Anti-VEGF mAb and anti-VEGFR2 mAb were attached on the liposome surface pH-sensitive carboxymethyl chitosan- modified liposomes DOX-loaded Amino-triphenyl dicarboxylate- bridged Zr4+ metal-organic framework Nanoparticles gated with a duplex nucleic acid including an anti-VEGF aptamer in a caged configuration Polycation liposome-encapsulated cal
Anti-cancer drug Not applicable cis-di-ammine- di-nitro- platinum (II) Not applicable DOX DOX HCl Gambogic acid Docetaxel Etoposide Paclitaxel Sorafenib Sorafenib Oral tablet Not applicable Paclitaxel
Antiangiogenic agent siRNA Not applicable Sorafenib and Cy3-siRNA Not applicable siRNA Gambogic acid siRNA siRNA Bevacizumab siRNA shRNA (Survivin) Vatalanib Sorafenib
Proangiogenic factor VEGF
